M&A Resurgence Puts Serial Acquirers In Focus

Global M&A activity has decisively rebounded, with both deal volume and megadeal value rising sharply after the recent trough. Large strategic buyers are again using acquisitions to accelerate growth, reshape portfolios, and consolidate fragmented niches.

Historical M&A upcycles, such as the mid‑2000s and 2013‑2016 healthcare wave, have typically rewarded sectors explicitly labeled as “in play,” where there is a deep bench of logical acquirers and targets. In those periods, sector indices and active consolidators often outperformed as investors assigned a sustained M&A premium.

Within the current upswing, healthcare and life sciences consolidators stand out. Thermo Fisher Scientific (TMO) and Danaher (DHR) both have long records of acquisition‑driven expansion in tools and diagnostics, and in prior life sciences M&A waves they benefited from investor confidence in their integration playbooks.

In broader healthcare, UnitedHealth Group (UNH) remains a key platform in managed care and health services, with ongoing deal activity through Optum. When healthcare is treated as “in play,” scaled payors and integrated platforms like UNH have historically attracted attention as both serial acquirers and central nodes in consolidation themes.

Industrials and aerospace also tend to feature in M&A rebounds, with portfolio reshaping and technology roll‑ups driving deal flow. Honeywell International (HON), with its exposure to automation, building technologies, and aerospace systems, fits the profile of a diversified consolidator that can use bolt‑on acquisitions to deepen capabilities when confidence and financing conditions support active dealmaking.